Testosterone Enanthate Dosing in Renal Impairment

Why Renal Impairment Changes the Clinical Picture

Testosterone enanthate is metabolized entirely by the liver through CYP3A4-mediated oxidation and subsequent glucuronidation [1]. The kidneys do not clear the parent compound or its active metabolites in clinically meaningful quantities. This pharmacokinetic profile means the FDA-approved labeling for Delatestryl carries no renal dosing adjustment [2].

The clinical reality is more complex. Chronic kidney disease (CKD) stages 3 through 5 alter testosterone pharmacology through indirect mechanisms: reduced albumin shifts free testosterone fractions, fluid overload changes volume of distribution, and uremia suppresses the hypothalamic-pituitary-gonadal axis at multiple levels [3]. A 2012 cross-sectional analysis of 2,032 men with eGFR <60 mL/min/1.73 m² found that 44% had total testosterone below 300 ng/dL, compared with 19.3% of age-matched controls with normal renal function [4]. The prevalence climbs higher in dialysis populations. Carrero et al. reported that 57% of male hemodialysis patients met biochemical criteria for hypogonadism [5].

These patients are not simply hypogonadal men who happen to have kidney disease. Their altered physiology demands a modified approach to testosterone replacement.

Pharmacokinetics in Reduced Renal Function

The esterified testosterone molecule (testosterone enanthate) is hydrolyzed in plasma and tissue to release free testosterone. This hydrolysis is enzyme-mediated and independent of glomerular filtration [1]. After intramuscular injection of 200 mg testosterone enanthate, peak serum concentrations reach approximately 1,200 ng/dL at 24 to 48 hours, declining to trough levels of 300 to 500 ng/dL by day 7 in euvolemic patients [6].

In CKD, two shifts matter. First, hypoalbuminemia (common in stages 4 to 5 and nephrotic-range proteinuria) increases free testosterone fraction relative to total testosterone. A patient with albumin of 2.8 g/dL may show a total testosterone of 350 ng/dL but a free testosterone that is already physiologically adequate [7]. Second, the expanded extracellular fluid volume in oliguric or anuric patients creates a larger distribution volume for the lipophilic ester depot, potentially blunting peak concentrations while extending the tail of the pharmacokinetic curve.

Hemodialysis does not remove testosterone enanthate. The compound is 98% protein-bound and has a molecular weight of 400.6 Da with high lipophilicity, characteristics that prevent meaningful dialytic clearance [2]. Timing injections relative to dialysis sessions is therefore unnecessary from a pharmacokinetic standpoint, though some practitioners prefer post-dialysis administration to avoid injection-site hematomas from intradialytic anticoagulation.

Recommended Starting Doses and Titration

The Endocrine Society's 2018 guideline on testosterone therapy in men with hypogonadism recommends initiating at doses that achieve mid-normal testosterone levels, with titration based on symptoms and serum levels [8]. For CKD patients, a conservative protocol reflects the heightened erythropoietic response and cardiovascular considerations.

CKD stages 3 to 3b (eGFR 30 to 59): Start at 100 mg intramuscularly every 7 days. This mirrors standard dosing but with a lower ceiling. Titrate by 25 mg increments no sooner than every 8 weeks, targeting trough total testosterone of 400 to 600 ng/dL.

CKD stages 4 to 5 (eGFR <30), not on dialysis: Start at 50 to 75 mg intramuscularly every 7 days. These patients have higher baseline erythropoietin sensitivity and greater cardiovascular event rates. The lower starting dose reduces the risk of polycythemia before steady state is reached at 4 to 6 weeks [9].

Hemodialysis or peritoneal dialysis: Start at 50 to 100 mg intramuscularly every 7 days. A 2020 randomized trial of 58 hypogonadal men on hemodialysis found that 100 mg/week testosterone enanthate raised mean total testosterone from 221 ng/dL to 548 ng/dL at 6 months, with hematocrit increases of 3.2 percentage points on average [10]. This erythropoietic effect may allow reduction of erythropoiesis-stimulating agent (ESA) doses, a clinically meaningful benefit given ESA costs and cardiovascular risks.

Dr. Alvin Matsumoto, Professor of Medicine at the University of Washington and principal investigator of the T-Trials, has noted: "The testosterone-deficient man with CKD requires the same physiologic replacement goal as any hypogonadal patient, but the monitoring cadence must be compressed because the hematologic response is amplified and less predictable."

Interaction with Erythropoiesis-Stimulating Agents

The overlap between testosterone's erythropoietic effect and exogenous ESA therapy creates a clinically significant interaction in dialysis patients. Testosterone stimulates erythropoiesis through three mechanisms: direct stimulation of erythroid progenitor cells, suppression of hepcidin (increasing iron availability), and upregulation of erythropoietin gene transcription in peritubular cells [11].

In the NDIT trial (N=120 hemodialysis patients), nandrolone decanoate (a related androgen) reduced ESA requirements by 33% over 6 months [12]. Testosterone enanthate produces comparable erythropoietic stimulation. Practical management requires ESA dose reduction of 20 to 40% within the first 8 weeks of testosterone initiation, with hematocrit checks every 2 to 4 weeks during this transition period.

If hematocrit exceeds 52%, testosterone dose should be reduced by 25 to 50%. If hematocrit exceeds 54%, hold testosterone until it drops below 50%, then restart at 50% of the prior dose [8]. These thresholds apply universally but carry particular weight in CKD populations where baseline hematocrits may already be managed to 33 to 36% targets.

Cardiovascular Risk Considerations in CKD

The intersection of testosterone replacement, cardiovascular disease, and CKD demands careful risk stratification. The TRAVERSE trial (N=5,204 men with cardiovascular disease or high cardiovascular risk) demonstrated non-inferiority of transdermal testosterone versus placebo for major adverse cardiovascular events (MACE) over a median 33-month follow-up (HR 0.96, 95% CI 0.78 to 1.17) [13]. This trial included men with eGFR as low as 30 mL/min/1.73 m² but excluded dialysis patients.

CKD stages 4 to 5 carry annual cardiovascular mortality rates of 10 to 20%, far exceeding the general population [14]. No randomized trial has been powered to assess MACE specifically in testosterone-treated dialysis patients. The 2018 Endocrine Society guideline recommends against initiating testosterone in men with recent (within 6 months) myocardial infarction or stroke, a caution that applies with greater force in the CKD population where subclinical cardiovascular disease is near-universal [8].

Fluid retention is another testosterone-mediated effect that intersects poorly with impaired renal sodium handling. Patients on testosterone enanthate who are oliguric or anuric should be monitored for weight gain exceeding 1 to 2 kg in the first month, with ultrafiltration targets adjusted if edema develops.

Monitoring Protocol for CKD Patients on Testosterone Enanthate

Standard monitoring recommendations from the Endocrine Society require adaptation for renal patients [8].

Baseline labs (before initiation): Total testosterone, free testosterone (equilibrium dialysis preferred), SHBG, albumin, CBC with differential, PSA, lipid panel, hepatic function, potassium, and morning cortisol if adrenal insufficiency is suspected.

Weeks 4 to 6: Trough total testosterone, free testosterone, hematocrit. In dialysis patients, pre-dialysis draw. Adjust ESA dose if hematocrit has risen more than 3 points from baseline.

Months 3 to 6: Repeat CBC, testosterone levels, PSA, potassium (testosterone can raise potassium via mineralocorticoid receptor interactions, compounding CKD-related hyperkalemia risk) [15]. Assess symptoms with validated instruments (qADAM or AMS scale).

Every 6 months thereafter: CBC, testosterone, PSA, metabolic panel. Annual DXA if osteoporosis was an indication. Semi-annual cardiovascular risk reassessment including blood pressure, weight, and volume status.

The 2014 T-Trials demonstrated significant improvement in sexual function (mean PDQ-Q4 increase of 0.58 vs. placebo, P<0.001), physical function (6-minute walk distance increase of 6.0 meters), and vitality (SF-36 vitality score increase of 2.41 points) in hypogonadal men aged 65 and older [16]. These benefits likely extend to CKD patients, though the magnitude may differ given their multifactorial fatigue and functional limitations.

Special Populations Within Renal Impairment

Kidney transplant recipients: Post-transplant hypogonadism affects 30 to 40% of male recipients, driven by prior uremic suppression, calcineurin inhibitor effects, and glucocorticoid use [17]. Testosterone enanthate is appropriate in this population, but CYP3A4 interactions with tacrolimus and cyclosporine may modestly alter testosterone metabolism. Monitor calcineurin inhibitor trough levels at 2 and 4 weeks after testosterone initiation.

Peritoneal dialysis patients: Intraperitoneal protein loss reduces SHBG and albumin, making total testosterone an unreliable marker. Free testosterone by equilibrium dialysis is the preferred measurement. Injection technique requires attention to avoiding the peritoneal catheter site. Subcutaneous injection of testosterone enanthate (same dose, 25-gauge needle, abdomen or thigh) is an acceptable alternative with similar pharmacokinetics [18].

Nephrotic syndrome without reduced GFR: Massive proteinuria can cause SHBG loss and factitious hypogonadism on total testosterone measurement. Confirm hypogonadism with free testosterone before initiating replacement. If genuine deficiency is confirmed, standard dosing applies as GFR is preserved.

When to Withhold or Discontinue

Absolute contraindications to testosterone enanthate remain unchanged by renal status: prostate or breast cancer, hematocrit above 54%, untreated severe obstructive sleep apnea, uncontrolled heart failure (NYHA class IV), and desire for fertility [8].

Relative contraindications with heightened relevance in CKD include: poorly controlled hypertension (systolic above 160 mmHg), recurrent AV fistula thrombosis (testosterone increases thromboxane A2), and severe hyperkalemia (potassium above 6.0 mEq/L) unresponsive to standard management.

Discontinuation should trigger gradual ESA dose increase to prevent precipitous hemoglobin decline. A reasonable approach: increase ESA by 25% at the time of testosterone cessation, recheck hemoglobin at 2 and 4 weeks, and titrate ESA to prior hemoglobin targets.

The American Urological Association recommends reassessing the indication for testosterone therapy annually [19]. In CKD patients who receive a kidney transplant and recover gonadal function (testosterone normalizes by 6 to 12 months post-transplant in approximately 50% of recipients), a supervised taper and discontinuation trial is appropriate.